Synopsis Approximately 30% of patients with type 2 diabetes mellitus have osteoarthritis (OA) of the knee. Limitation of mobility in diabetic patients with osteoarthritis is a risk factor for diabetes-related complications including hyperglycemia. The present study assesses the effects of triamcinolone acetonide extended-release injection on blood glucose in patients With OA of the Knee and Type 2 Diabetes. This week’s “ MED FACT ” discusses a randomized control trial from Rheumatology, “ Triamcinolone acetonide extended-release in patients with osteoarthritis and type 2 diabetes: a randomized, phase 2 study ”. Authors: S.
J. Russell, et. al. Key Takeaways Glucose levels were more stable with extended-release versus standard triamcinolone acetonide when administered in patients with OA and diabetes. Objective: The purpose of this study was to compare the effects of extended-release with…
